A patient tells you their vision “goes in and out” after a few minutes on screens, their eyes burn in the car with the vents on, and drops help for about ten minutes. If you only chase aqueous deficiency, you will miss the dominant driver in a large share of symptomatic dry eye: meibomian gland dysfunction (MGD). The clinics that diagnose MGD efficiently do two things well - they standardize what they look for and they document it in a way that supports repeatable care pathways.
What you are actually diagnosing in MGD
MGD is not a single finding. Clinically, you are diagnosing a functional problem (obstructed or hyposecreting glands and unstable lipid layer) that produces downstream ocular surface stress. That matters because symptoms often correlate poorly with corneal staining, while correlating better with evaporative dynamics and lid margin disease.
The practical goal is to determine (1) whether the meibomian glands are contributing meaningfully to the patient’s complaints, (2) severity and stage, and (3) whether inflammation is a primary feature. That informs whether you start with lid hygiene and anti-inflammatory management, move quickly to in-office expression/thermal approaches, or add point-of-care therapies that target chronic inflammation and meibum viscosity.
How to diagnose meibomian gland dysfunction: a clinic workflow
A useful MGD workup is short, consistent, and technician-friendly. You do not need every test on every patient, but you do need a sequence that reduces variability.
Step 1: Targeted history that predicts evaporative disease
Start with questions that separate dryness sensation from evaporative triggers. Screen time intolerance, wind/vent sensitivity, contact lens discomfort late in the day, and fluctuating vision that improves after blinking are common MGD flags. Ask about rosacea, eyelid inflammation history, blepharitis treatment, omega-3 use, and systemic meds that alter blink or meibum quality.
It also helps to document the patient’s “why now.” New symptoms after refractive surgery, mask-associated dryness, or menopause-related changes can push borderline MGD into symptomatic disease. Your diagnosis is stronger when it links symptoms to a plausible change in tear film stability.
Step 2: External exam and blink assessment
Before drops, watch the blink. Incomplete blinking and reduced blink rate during conversation are common in evaporative dry eye. Note lid laxity, lagophthalmos, or dermatochalasis that contributes to exposure. These are not “MGD” per se, but they change your management and explain why expression alone may underperform.
Step 3: Slit lamp evaluation of the lid margin
At the slit lamp, focus on lid margin anatomy and the meibomian orifices. Look for telangiectasia, posterior lid margin rounding, notching, capped or pouting orifices, and anterior blepharitis that can coexist. A clean-looking lid margin does not exclude MGD - you still need gland function.
Tear film assessment belongs here too. A thin or irregular lipid layer, debris, and rapid tear breakup are consistent with evaporative disease. If you have a digital slit lamp workflow, capturing standardized lid margin photos can dramatically improve follow-up comparisons and patient acceptance.
Step 4: Meibomian gland expression (the diagnostic inflection point)
Expression is where many clinics either diagnose MGD confidently or hedge. Standardize your approach. Apply consistent pressure to a defined set of central lower lid glands and document both quality and quantity.
You are looking for easily expressible, clear meibum versus turbid, toothpaste-like, granular, or absent secretions. Low yield with significant patient discomfort suggests obstruction and inflammation. High yield but turbid secretions often suggests altered meibum composition.
Trade-off: aggressive expression can transiently worsen symptoms in highly inflamed lids, and it can create an impression of “no glands” if pressure is inconsistent. Training and a repeatable tool or technique matter for diagnostic reliability.
Step 5: Tear breakup time and ocular surface staining
Non-invasive TBUT (if available) is ideal because fluorescein itself can alter breakup. If you use fluorescein TBUT, be consistent with volume and timing. A short TBUT supports evaporative dysfunction but is not specific to MGD.
Staining helps you stage surface impact and rule in mixed disease. Significant inferior staining with relatively mild symptoms can point to exposure or lid wiper epitheliopathy. Minimal staining with severe symptoms can still be MGD, especially early-stage or neuropathic overlay. Documenting these mismatches is clinically useful because it keeps you from over-treating the surface while under-treating the lids.
Step 6: Meibography and structured dry eye metrics (when you want speed and documentation)
Meibography adds a structural layer: dropout, truncation, and gland tortuosity. It is not required for every diagnosis, but it is valuable for (1) baseline documentation, (2) motivating adherence, and (3) triaging severity quickly across multiple providers.
A dedicated dry eye analyzer can also standardize metrics like non-invasive TBUT, tear meniscus height, and imaging-based assessment depending on the platform. The clinical win is throughput - techs can capture objective data in-room, leaving the provider to interpret patterns and decide the pathway.
The key nuance: gland dropout does not perfectly predict symptoms. Some patients with marked dropout are comfortable, while others with minimal dropout are miserable. Structural imaging should support - not replace - functional testing and clinical judgment.
Step 7: Classify severity in a way your clinic can execute
You do not need a complicated staging system to be consistent. Most clinics can operationalize MGD severity using three anchors: symptoms (frequency and triggers), expressibility/meibum quality, and gland structure (if imaged). Add inflammatory signs (telangiectasia, lid tenderness, thickened margin) as a modifier.
This classification should map directly to treatment lanes. Mild disease can be home-based plus targeted anti-inflammatory options. Moderate to severe obstruction often benefits from in-office interventions. Chronic inflammatory phenotypes may need a longer runway and tighter follow-up intervals.
Common diagnostic traps (and how to avoid them)
The biggest trap is assuming that “dry eye” equals aqueous deficiency. A normal tear meniscus does not exclude MGD. Another trap is relying on symptoms alone. Patients with high symptom burden and minimal signs may have neuropathic pain components, but that does not mean MGD is absent - it means you should be cautious about escalating mechanical treatments without addressing inflammation and sensation.
Contact lens patients create a separate pitfall. Lens-related dryness can mimic MGD, but MGD also drives end-of-day discomfort. Expression findings and TBUT trends help you decide whether the lens is the irritant or the lid is.
Finally, do not ignore the upper lid. Many quick exams focus on the lower lid only. Upper lid gland status and dropout can be a major driver, especially in long-term contact lens wearers.
Turning diagnosis into a repeatable, billable care pathway
MGD diagnosis is most valuable when it is trackable. That means you need documentation that can be repeated at follow-ups: lid margin photos, a consistent expression score, TBUT, staining, and (when used) meibography.
Clinics expanding dry eye services typically do well with portable, point-of-care imaging because it reduces room dependence and makes technician capture easier across locations. If you are building a modern dry eye workflow with diagnostic and treatment capability designed for throughput, a consolidated equipment catalog like OcuRx can simplify procurement for in-room imaging, dry eye diagnostics, and therapy expansion without relying on large-footprint capital systems.
A practical note on ROI: patients are more likely to accept in-office MGD procedures when you can show them objective findings - capped orifices, altered meibum quality on expression, and gland loss or truncation. Visual proof shortens the conversation and reduces the perception that you are treating “just dry eye.”
When to refer or broaden the differential
MGD can coexist with allergic conjunctivitis, demodex-related lid disease, autoimmune dry eye, and exposure keratopathy. If symptoms are severe with disproportionate photophobia, marked pain, or poor response to appropriate MGD care, consider corneal neuralgia, toxic exposure, or herpetic disease depending on the presentation.
Also consider that significant lid margin inflammation with facial rosacea may benefit from coordinated dermatologic management. Your MGD diagnosis remains correct, but outcomes improve when systemic drivers are addressed.
Closing thought: the fastest way to improve MGD outcomes is not a new test - it is consistency. When every patient gets the same short set of pre-drop observations, standardized expression documentation, and objective imaging when appropriate, your treatment decisions get easier, your follow-ups get cleaner, and your dry eye clinic becomes more predictable to run.